Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 2
- 主要终点
- Clinical efficacy, in terms of overall response rate, measured by serum prostate-specific antigen (PSA) levels every 3 months
研究概览
简要总结
RATIONALE: Pomegranate juice may contain substances that decrease or slow the rise of prostate-specific antigen (PSA) levels and may be effective in delaying or preventing recurrent prostate cancer.
PURPOSE: This phase II trial is studying how well pomegranate juice works in decreasing or slowing the rise of PSA levels in patients who have undergone radiation therapy or surgery for prostate cancer.
详细描述
OBJECTIVES:
- Determine whether pomegranate juice can decrease or slow rising prostate-specific antigen (PSA) levels in patients who have undergone radical prostatectomy or radiotherapy for adenocarcinoma of the prostate.
OUTLINE: Patients receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 29-40 patients will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of the prostate
- •Must have undergone prior surgery or radiotherapy for the primary tumor
- •Documented rising prostate-specific antigen (PSA) level, defined by the following criteria:
- •Absolute level of PSA at least 0.2 ng/mL but less than 5.0 ng/mL
- •Rising PSA level must be confirmed at least 1 week later
- •Adequate PSA time points to calculate a PSA doubling time
- •Gleason score no greater than 7
- •Age 18 and over
- •Performance status ECOG 0-1
- •Life expectancy at least 6 months
- •No other malignancy within the past 5 years except nonmelanoma skin cancer
- •No other serious concurrent systemic medical disorders that would preclude study compliance
- •No known allergy to pomegranate juice
- •More than 4 weeks since prior participation in another experimental study
排除标准
- •nodal involvement
- •evidence of metastatic disease
- •prior hormonal therapy
- •concurrent hormonal therapy for rising PSA levels after initial therapy for prostate cancer
- •concurrent participation in another experimental study
- •other concurrent systemic or local therapy for prostate cancer
- •initiation or discontinuation of any new nutritional or dietary supplements during study participation
结局指标
主要结局
Clinical efficacy, in terms of overall response rate, measured by serum prostate-specific antigen (PSA) levels every 3 months
时间窗: Evaluated every 3 months for 18 months
次要结局
未报告次要终点